North American Neural Implants Market 2025-2035

Description

List of Tables

North American Neural Implants Market Size, Share & Trends Analysis Report by Product (Deep Brain Stimulation (DCS), Spinal Cord Stimulation (SCS), and Vagus Nerve Stimulation (VNS)), by Application (Chronic Pain, Epilepsy, Parkinson's Disease (PD), and Others (Depression and Other Movement Disorders)), and by End-user (Hospitals, Outpatient Surgery Centers, and Specialized Neurological Centers (SNCs)), Forecast Period (2025-2035)

Industry Overview

North American neural implants market was valued at $3.16 billion in 2024 and is projected to reach $11.3 billion by 2035, growing at a CAGR of 12.3% during the forecast period (2025-2035). The North American neural implants market is witnessing steady growth, primarily driven by the rising adoption of advanced neuromodulation therapies for neurological disorders. The increasing prevalence of conditions such as Parkinson's disease, epilepsy, and chronic pain has created a strong demand for innovative implantable solutions. Companies are introducing highly precise devices that improve patient outcomes and enhance quality of life. Technological advancements, including miniaturized implants and improved battery longevity, are further supporting market expansion. Strategic collaborations between medical device manufacturers and research institutions are accelerating product development. Additionally, growing awareness among healthcare providers and patients about the benefits of neural implants is contributing to broader market acceptance.

Market Dynamics

Advancements in Brain-Computer Interface (BCI) Technologies

The North American neural implants market is experiencing significant growth, driven by innovations in brain-computer interface (BCI) technologies. Companies like Paradromics are at the forefront, having successfully tested their Connexus implant in human trials. This device aims to restore communication abilities in individuals with conditions such as paralysis and ALS by translating neural signals into speech and text. The success of such trials underscores the potential of BCIs to revolutionize treatment options for patients with severe neurological impairments.

Integration of Artificial Intelligence in Neural Implants

Artificial intelligence (AI) is increasingly being integrated into neural implant technologies, enhancing their functionality and adaptability. For instance, Cognixion has developed the Cognixion ONE Axon, a non-invasive BCI that utilizes AI to interpret neural signals, enabling individuals with speech impairments to communicate effectively. The incorporation of AI allows for more precise decoding of neural activity, leading to improved user experience and broader applicability of neural implants in treating various neurological disorders.

Market Segmentation

Based on the product, the market is segmented into deep brain stimulation (DCS), spinal cord Stimulation (SCS), and vagus nerve stimulation (VNS).
Based on the application, the market is segmented into chronic pain, epilepsy, Parkinson's Disease (PD), and Others (depression and other movement disorders).
Based on the end-user, the market is segmented into hospitals, outpatient surgery centers, and specialized neurological centers (SNCs).

Deep Brain Stimulation (DBS) Segment to Lead the Market with the Largest Share

The North American neural implants sector is experiencing robust growth driven by advancements in Deep Brain Stimulation (DBS) technology. Medtronic has introduced its Percept PC neurostimulator, which allows real-time brain signal monitoring and personalized therapy adjustments. Boston Scientific's Vercise system supports precise DBS treatment for movement disorders, enhancing patient outcomes. Increasing awareness of neurological disorders and rising investments in research further fuel market expansion. Hospitals and specialized clinics are increasingly adopting these systems, reflecting a strong demand trajectory. Continuous innovation in implantable devices is expected to sustain long-term growth in the region.

Parkinson's Disease (PD): A Key Segment in Market Growth

The prevalence of Parkinson's Disease is a significant factor propelling the North American neural implants market. Abbott's Infinity DBS system provides adaptive stimulation to manage PD symptoms effectively, improving the quality of life for patients. Medtronic's Activa series continues to gain traction among neurosurgeons for advanced PD management. The rising number of PD cases, combined with increased healthcare spending, is accelerating adoption. Academic medical centers are also expanding DBS programs to meet patient demand. Technological enhancements, including closed-loop systems, are anticipated to further drive market growth.

Regional Outlook

The North American neural implants market is further divided by countries, including the US and Canada.

US Dominates the Market with a Major Share

The US neural implants market is expanding owing to the growing need for advanced neurological therapies. Companies such as Boston Scientific offer the Vercise DBS platform, providing targeted brain stimulation for movement and mood disorders. Medtronic's Percept PC system enables data-driven therapy adjustments, increasing clinical precision. The rising incidence of chronic neurological conditions and an aging population are key growth factors. Investments in R&D and regulatory approvals for innovative implants further support market penetration. Increasing adoption in hospitals, outpatient centers, and research institutions reflects the market's dynamic expansion.

Market Players Outlook

The major companies operating in the North American neural implants market include Abbott Laboratories, Boston Scientific Corp., Medtronic plc, Neuralink Corp., Synchron Inc., and others. The companies are pursuing partnerships, collaborations, mergers, and acquisitions to drive innovation, expand product portfolios, enhance sustainability, and strengthen market presence. These strategies enable players to respond to growing demand for energy-efficient, high-performance insulation solutions across residential, commercial, and industrial applications while maintaining a competitive edge.

Recent Developments

In June 2025, a paralyzed US military veteran was implanted with the revolutionary Neuralink brain-computer device by surgeons at The Miami Project to Cure Paralysis and the Department of Neurological Surgery at the University of Miami Miller School of Medicine. The PRIME Study is an investigational medical device clinical trial for assessing the safety and functionality of Neuralink's intracortical brain-computer interface (BCI) implant, which establishes a wireless, digital link between the brain and computers.
In April 2025, the neurotech startup announced that a core component of its brain implant system had been approved by the FDA. Precision is building a brain-computer interface, or a BCI, that will initially be used to help patients with severe paralysis restore functions such as speech and movement.

The Report Covers:

Market value data analysis of 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the North American neural implants market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2023490

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
North American Neural Implants Market Sales Analysis - Product | Application | End-User | ($ Million)
North American Neural Implants Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key North American Neural Implants Industry Trends
- 2.2.2. Market Recommendations

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For North American Neural Implants Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For North American Neural Implants Market: Impact Analysis
3.3. Market Opportunities

4. Competitive Landscape

4.1. Competitive Dashboard - North American Neural Implants Market Revenue and Share by Manufacturers
Neural Implants Product Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. Abbott Laboratories
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis (Subject to Data Availability)
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Boston Scientific Corp.
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis (Subject to Data Availability)
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Medtronic plc
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis (Subject to Data Availability)
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Neuralink Corp.
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis (Subject to Data Availability)
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Synchron Inc.
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis (Subject to Data Availability)
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. North American Neural Implants Market Sales Analysis by Product ($ Million)

5.1. Deep Brain Stimulation (DCS)
5.2. Spinal Cord Stimulation (SCS)
5.3. Vagus Nerve Stimulation (VNS)

6. North American Neural Implants Market Sales Analysis by Application ($ Million)

6.1. Chronic Pain
6.2. Epilepsy
6.3. Parkinson's Disease (PD)
6.4. Others (Depression and Other Movement Disorders)

7. North American Neural Implants Market Sales Analysis by End-User ($ Million)

7.1. Hospitals
7.2. Outpatient Surgery Centers
7.3. Specialized Neurological Centers (SNCs)

8. Regional Analysis

8.1. North American Neural Implants Market Sales Analysis - Product | Application | End-User | Country ($ Million)
Macroeconomic Factors for North American
- 8.1.1. US
- 8.1.2. Canada

9. Company Profiles

9.1. Abbott Laboratories
- 9.1.1. Quick Facts
- 9.1.2. Company Overview
- 9.1.3. Product Portfolio
- 9.1.4. Business Strategies
9.2. Aleva Neurotherapeutics SA
- 9.2.1. Quick Facts
- 9.2.2. Company Overview
- 9.2.3. Product Portfolio
- 9.2.4. Business Strategies
9.3. Blackrock Neurotech
- 9.3.1. Quick Facts
- 9.3.2. Company Overview
- 9.3.3. Product Portfolio
- 9.3.4. Business Strategies
9.4. Boston Scientific Corp.
- 9.4.1. Quick Facts
- 9.4.2. Company Overview
- 9.4.3. Product Portfolio
- 9.4.4. Business Strategies
9.5. ClearPoint Neuro
- 9.5.1. Quick Facts
- 9.5.2. Company Overview
- 9.5.3. Product Portfolio
- 9.5.4. Business Strategies
9.6. Fisher Wallace Laboratories Inc.
- 9.6.1. Quick Facts
- 9.6.2. Company Overview
- 9.6.3. Product Portfolio
- 9.6.4. Business Strategies
9.7. Functional Neuromodulation Ltd.
- 9.7.1. Quick Facts
- 9.7.2. Company Overview
- 9.7.3. Product Portfolio
- 9.7.4. Business Strategies
9.8. LivaNova plc
- 9.8.1. Quick Facts
- 9.8.2. Company Overview
- 9.8.3. Product Portfolio
- 9.8.4. Business Strategies
9.9. Medtronic plc
- 9.9.1. Quick Facts
- 9.9.2. Company Overview
- 9.9.3. Product Portfolio
- 9.9.4. Business Strategies
9.10. Neuralink Corp.
- 9.10.1. Quick Facts
- 9.10.2. Company Overview
- 9.10.3. Product Portfolio
- 9.10.4. Business Strategies
9.11. NeuroOne Medical Technologies, Inc.
- 9.11.1. Quick Facts
- 9.11.2. Company Overview
- 9.11.3. Product Portfolio
- 9.11.4. Business Strategies
9.12. NeuroPace, Inc.
- 9.12.1. Quick Facts
- 9.12.2. Company Overview
- 9.12.3. Product Portfolio
- 9.12.4. Business Strategies
9.13. NeuroSky Inc.
- 9.13.1. Quick Facts
- 9.13.2. Company Overview
- 9.13.3. Product Portfolio
- 9.13.4. Business Strategies
9.14. Neurospine LLC
- 9.14.1. Quick Facts
- 9.14.2. Company Overview
- 9.14.3. Product Portfolio
- 9.14.4. Business Strategies
9.15. ONWARD Medical NV
- 9.15.1. Quick Facts
- 9.15.2. Company Overview
- 9.15.3. Product Portfolio
- 9.15.4. Business Strategies
9.16. Paradromics Inc.
- 9.16.1. Quick Facts
- 9.16.2. Company Overview
- 9.16.3. Product Portfolio
- 9.16.4. Business Strategies
9.17. Renishaw plc
- 9.17.1. Quick Facts
- 9.17.2. Company Overview
- 9.17.3. Product Portfolio
- 9.17.4. Business Strategies
9.18. SceneRay Co., Ltd.
- 9.18.1. Quick Facts
- 9.18.2. Company Overview
- 9.18.3. Product Portfolio
- 9.18.4. Business Strategies
9.19. Synchron Inc.
- 9.19.1. Quick Facts
- 9.19.2. Company Overview
- 9.19.3. Product Portfolio
- 9.19.4. Business Strategies
9.20. Synergia Medical
- 9.20.1. Quick Facts
- 9.20.2. Company Overview
- 9.20.3. Product Portfolio
- 9.20.4. Business Strategies